Clinical Trials Logo

Heart Failure clinical trials

View clinical trials related to Heart Failure.

Filter by:

NCT ID: NCT05839067 Recruiting - Heart Failure Clinical Trials

Supporting Health in Veterans With Heart Failure

CARE-HF
Start date: May 31, 2023
Phase: N/A
Study type: Interventional

This study will test the effectiveness of a culturally-sensitive, telephone-based, tailored problem-solving intervention to improve physical and mental health in Veterans with heart failure (HF). Veterans will be recruited from VA clinics throughout the United States. As a component of this study, Veterans will partner with a registered nurse for a 12-week telehealth program that includes 8 telephone sessions. Follow-up data will be collected at 3-months (post intervention) and 6-, 12-, and 18-months to examine sustainability of intervention effect.

NCT ID: NCT05839028 Active, not recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction

Mechanisms of LV Remodeling in Hypertensive Patients Working on a Rotational Expeditionary Basis in the Arctic

Start date: October 16, 2022
Phase:
Study type: Observational [Patient Registry]

The main goal of our investigation is to study the mechanisms of formation of left ventricular remodeling in patients with hypertension, working on a rotational expedition basis in the Arctic.

NCT ID: NCT05838937 Not yet recruiting - Cardiogenic Shock Clinical Trials

The Usefulness of Myocardial Work IndeX in ExtraCorporeal Membrane Oxygenation Patients

MIX-ECMO
Start date: June 1, 2024
Phase:
Study type: Observational [Patient Registry]

Investigation of the potential prognostic role of non-invasive myocardial work in patients receiving veno-arterial extracorporeal membrane oxygenation therapy.

NCT ID: NCT05838287 Recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction

Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants

PIOHF
Start date: July 10, 2023
Phase: Phase 4
Study type: Interventional

Our goal of the study is to learn the effects of the diabetes medication named Pioglitazone, in type-2 diabetic obese participants with Heart failure. The main question it aims to answer are: 1. To demonstrate that impaired mitochondrial function leading to reduced ATP generation plays a key pathophysiologic role in the development of heart failure with preserved ejection fraction (HFpEF) in obese type 2 diabetic (T2D) individuals. 2. To demonstrate that pioglitazone, improves diastolic (as well as systolic) function by improving myocardial insulin sensitivity and by reducing both myocardial and epicardial fat content.

NCT ID: NCT05837143 Recruiting - Heart Failure Clinical Trials

Myocardial Telomere Recapping Study for Dilated Cardiomyopathy

MERCURY-DCM
Start date: April 6, 2023
Phase: Early Phase 1
Study type: Interventional

The aim of this study is to determine the safety and feasibility of giving an adeno-associated viral vector expressing a modified telomerase protein (TERT), driven by cardiac troponin T promoter (AAV9-cTnT-modTERT), to 15 dilated cardiomyopathic patients.

NCT ID: NCT05836233 Recruiting - Right Heart Failure Clinical Trials

Predictive Value of Vasodilator Challenge for Right Heart Failure After LVAD Implantation

PREVV-RHF-LVAD
Start date: February 15, 2023
Phase:
Study type: Observational [Patient Registry]

Prospective evaluation of the predictive value for post-LVAD right ventricular failure (RHF) of pulmonary vasodilator challenge, in addition to current laboratory, echocardiographic and haemodynamic parameters. LVAD candidates satisfying the inclusion criteria will undergo vasodilator challenge with sodium nitroprusside (NTP) infusion following the study protocol. Thereafter, we will evaluate all data in order to determine which variables significantly correlate with RHF onset after LVAD implantation.

NCT ID: NCT05835063 Completed - Clinical trials for Heart Failure NYHA Class III

A Study to Improve Physician-Youth Communication and Medical Decision Making

CHATT
Start date: September 14, 2023
Phase: N/A
Study type: Interventional

The goal of this study is improving patient-centered communication for young people with advanced heart disease.

NCT ID: NCT05835024 Recruiting - Heart Failure Clinical Trials

Acorai MLG Study (Machine Learning Generalisation)

Start date: August 15, 2023
Phase:
Study type: Observational

Acorai is developing a non-invasive monitoring system for the estimation of intracardiac hemodynamic parameters in patients with suspected or confirmed heart failure, and/or pulmonary hypertension, who require hemodynamic assessment. The device will be intended as a companion test or clinical decision support tool to be used and interpreted by qualified healthcare professionals to aid standard-of-care clinical assessment in identifying hemodynamic congestion and supporting personalized treatment of heart failure and pulmonary congestion. This study is part of the development of a non-invasive monitoring system for the estimation of intracardiac hemodynamic parameters. It will be conducted to collect the data needed to train the machine learning models retrospectively.

NCT ID: NCT05834803 Recruiting - Heart Failure Clinical Trials

Effects of Percutaneous Transluminal Renal Angioplasty of Atherosclerotic Renal Artery Stenosis in High-Risk Patients.

DAN-PTRAII
Start date: June 26, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to document a beneficial effect of percutaneous transluminal renal angioplasty (PTRA) of atherosclerotic renal artery stenosis in high-risk patients selected according to the criteria used in the DAN-PTRA study. The main questions the trial aims to answer are if renal artery stenting compared with optimal medical treatment alone has beneficial effects on: - Blood pressure - Kidney function - Hospitalizations for heart failure

NCT ID: NCT05834400 Recruiting - Heart Failure Clinical Trials

Lymphatic System Stimulation in Heart Failure

Start date: June 15, 2023
Phase: N/A
Study type: Interventional

The goal of this pilot clinical trial is to obtain preliminary data on the effects of lymphatic exercise training in patients with heart failure. The main question[s] it aims to answer are: 1. Does performing lymphatic exercise decrease fluid overload symptoms (shortness of breath, lower legs swelling, fatigue), thoracic fluid content, and body fluid level? 2. Does performing lymphatic exercise improve sleep and quality of life (QOL)? Participants with heart failure will be randomly assigned into two groups: Group 1 will receive training on lymphatic exercises, and will perform these training for 4 weeks. This group will also be trained to monitor daily their weight, heart rate and blood pressure, and fluid overload symptoms. Group 2 will be trained to daily monitor their weight, heart rate and blood pressure, and fluid overload symptoms. This group will not perform the lymphatic exercises. Researchers will compare the two groups at the baseline and after delivering the 4 week-interventions to see 1. if lymphatic exercise helped decrease symptoms associated with fluid overload like shortness of breath, lower leg swelling, and fatigue. 2. if lymphatic exercises decreased thoracic fluid content and total body fluid level . 3. if the lymphatic exercise helped improve sleep and quality of life (QOL).